Halozyme Therapeutics, Inc.
Hedge Funds Holdings
Last updated:
Halozyme Therapeutics, Inc.‘s stocks are currently a part of 300 hedge funds’ portfolios, which represents 85.16% of the total amount of its stocks outstanding. This makes up a total of 125.01M shares of Halozyme Therapeutics, Inc.. Compared to the previous quarter, the number fell by -1.93% or -2.45M shares fewer. As for the holding position changes, 35.33% (106) of current hedge fund investors increased the number of shares held, 40% (120) of current holders sold a part of the shares held, and 12% (36) closed the holdings completely. 29 hedge funds are new holders of Halozyme Therapeutics, Inc. stock in Q1 2022, it is 9.67% of total holders.
Hedge funds holding Halozyme Therapeutics (Q2 2017 – Q1 2022)
| Q2 2017 | 167 |
|---|---|
| Q3 2017 | 166 |
| Q4 2017 | 198 |
| Q1 2018 | 208 |
| Q2 2018 | 192 |
| Q3 2018 | 191 |
| Q4 2018 | 192 |
| Q1 2019 | 198 |
| Q2 2019 | 200 |
| Q3 2019 | 208 |
| Q4 2019 | 219 |
| Q1 2020 | 206 |
| Q2 2020 | 261 |
| Q3 2020 | 264 |
| Q4 2020 | 336 |
| Q1 2021 | 331 |
| Q2 2021 | 308 |
| Q3 2021 | 315 |
| Q4 2021 | 315 |
| Q1 2022 | 300 |
Hedge funds changes in Halozyme Therapeutics positions (Q2 2017 – Q1 2022)
| Q2 2017 | 26 | 75 | 41 | 17 | 8 |
|---|---|---|---|---|---|
| Q3 2017 | 16 | 65 | 54 | 14 | 17 |
| Q4 2017 | 49 | 69 | 54 | 16 | 10 |
| Q1 2018 | 38 | 69 | 65 | 23 | 13 |
| Q2 2018 | 17 | 69 | 72 | 32 | 2 |
| Q3 2018 | 20 | 65 | 66 | 20 | 20 |
| Q4 2018 | 32 | 68 | 58 | 30 | 4 |
| Q1 2019 | 25 | 66 | 63 | 18 | 26 |
| Q2 2019 | 26 | 79 | 61 | 19 | 15 |
| Q3 2019 | 30 | 64 | 72 | 22 | 20 |
| Q4 2019 | 50 | 76 | 64 | 32 | -3 |
| Q1 2020 | 33 | 56 | 85 | 44 | -12 |
| Q2 2020 | 72 | 90 | 72 | 14 | 13 |
| Q3 2020 | 33 | 89 | 98 | 27 | 17 |
| Q4 2020 | 98 | 103 | 106 | 26 | 3 |
| Q1 2021 | 48 | 124 | 127 | 47 | -15 |
| Q2 2021 | 28 | 123 | 108 | 46 | 3 |
| Q3 2021 | 41 | 136 | 96 | 30 | 12 |
| Q4 2021 | 37 | 125 | 116 | 41 | -4 |
| Q1 2022 | 29 | 106 | 120 | 36 | 9 |
Hedge funds changes in Halozyme Therapeutics stock options (Q2 2017 – Q1 2022)
| Q2 2017 | 34,864,000 | 4,302,000 |
|---|---|---|
| Q3 2017 | 63,683,000 | 6,946,000 |
| Q4 2017 | 61,977,000 | 24,949,000 |
| Q1 2018 | 30,041,000 | 11,054,000 |
| Q2 2018 | 10,362,000 | 5,364,000 |
| Q3 2018 | 10,798,000 | 5,085,000 |
| Q4 2018 | 11,537,000 | 5,540,000 |
| Q1 2019 | 12,196,000 | 4,281,000 |
| Q2 2019 | 18,074,000 | 3,251,000 |
| Q3 2019 | 13,770,000 | 5,030,000 |
| Q4 2019 | 22,330,000 | 7,154,000 |
| Q1 2020 | 9,370,000 | 4,568,000 |
| Q2 2020 | 35,770,000 | 7,496,000 |
| Q3 2020 | 23,554,000 | 6,526,000 |
| Q4 2020 | 22,827,000 | 5,928,000 |
| Q1 2021 | 18,822,000 | 13,130,000 |
| Q2 2021 | 26,857,000 | 19,688,000 |
| Q3 2021 | 21,995,000 | 8,559,600 |
| Q4 2021 | 22,652,000 | 678,416,943 |
| Q1 2022 | 21,581,000 | 4,120,000 |